OCUL
- Ocular Therapeutix, Inc.
()
Overview
Company Summary
Ocular Therapeutix, Inc. is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for diseases and conditions affecting the eyes. They specialize in creating sustained-release drug delivery products, which aim to provide long-lasting and effective drug treatments for ocular disorders.
The company's main technology platform is called hydrogel-based drug delivery. They use a proprietary polyethylene glycol (PEG) hydrogel matrix to develop therapeutic products that can release drugs over an extended period of time. This technology enables sustained drug release directly into the eye, reducing the need for frequent eye drops or injections.
Ocular Therapeutix's product pipeline includes treatments for various eye conditions. One of their key products is Dextenza, which is an FDA-approved intracanalicular depot that delivers dexamethasone to the eye. It is used to treat ocular pain and inflammation following ophthalmic surgery.
In addition to Dextenza, the company is developing multiple other sustained-release drug candidates to target different eye conditions, including glaucoma, allergic conjunctivitis, and dry eye disease. Their goal is to improve patient outcomes and convenience by providing sustained drug delivery solutions that reduce the burden of frequent dosing.
Overall, Ocular Therapeutix is dedicated to leveraging its proprietary drug delivery technology to develop innovative therapies and address unmet needs in the field of ophthalmology, ultimately aiming to enhance the lives of patients with eye diseases.